Literature DB >> 6994913

The practical benefits of pharmacokinetics in the use of antineoplastic agents.

C Erlichman, R C Donehower, B A Chabner.   

Abstract

Mesh：

Substances：

Year:  1980        PMID： 6994913     DOI： 10.1007/bf00254011

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  63 in total

1.  Gas chromatographic determination of hexamethylmelamine in mouse plasma.

Authors:  M D'Incalci; P Morazzoni; C Pantarotto
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

4.  A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.

Authors:  R G Hahn; C G Moertel; A J Schutt; H W Bruckner
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

5.  The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals.

Authors:  V T DeVita; C Denham; J D Davidson; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1967 Jul-Aug       Impact factor: 6.875

6.  Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.

Authors:  Y Wang; E Lantin; W W Sutow
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

7.  Comparison of two radioimmunoassays and a microbiologic assay for bleomycin.

Authors:  M K Elson; M M Oken; R B Shafer; A Broughton; J Strong; C T Braun; S T Crooke
Journal:  Med Pediatr Oncol       Date:  1978

8.  Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma.

Authors:  J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

9.  Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.

Authors:  C E Myers; R C Young; B A Chabner
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640
View more
  8 in total

1.  Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma.

Authors:  J A Nelson; J A Hokanson; V K Jenkins
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

4.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

5.  A radioimmunoassay for VP16-213 in plasma.

Authors:  G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

7.  Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.

Authors:  C J Brindley; P Antoniw; E S Newlands; K D Bagshawe
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.